Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

458.70 +7.73 (+1.72%)
Streaming Delayed Price Updated: 10:13 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
53 54 Next >
Analyst Expectations for Vertex Pharmaceuticals's Future
Via Benzinga
Vertex Pharmaceuticals Just Lost a Potential Rival. Is the Stock a Buy?
Vertex dominates the cystic fibrosis market today. 
Via The Motley Fool
Baird Maintains Neutral Rating for Vertex Pharmaceuticals: Here's What You Need To Know
Via Benzinga
2 Supercharged Stocks to Buy for 2023 and Hold for at Least 10 Years
These businesses are leaders in their respective industries, but aren't close to done growing. 
Via The Motley Fool
2 Incredible Growth Stocks That Could Turn $20,000 Into $100,000 by 2030
These growth stocks each have a competitive edge in their respective industries. 
Via The Motley Fool
Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie
One big drugmaker's pain translates into another big drugmaker's gain. 
Via The Motley Fool
Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives
Vertex expects $9.55 billion to $9.7 billion in full-year product sales. 
Via Investor's Business Daily
Earnings Outlook For Vertex Pharmaceuticals
Via Benzinga
2 Growth Stocks That Could Double in 5 Years
Both of these companies did more than that in the past five years. 
Via The Motley Fool
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
Vertex Pharmaceuticals (VRTX) Q1 2023 Earnings Call Transcript
VRTX earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Vertex Reports First Quarter 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector
A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro... 
Via Talk Markets
The Best Stocks to Invest $5,000 in Right Now
These appear to be the ideal stocks in times like these. 
Via The Motley Fool
2 Stocks That Could Turn $200,000 Into $1 Million by the Time You Retire
Planning for the long term starts now. 
Via The Motley Fool
Earnings Scheduled For May 1, 2023
Companies Reporting Before The Bell • TG Therapeutics (NASDAQ:TGTX) is estimated to report quarterly loss at $0.37 per share on revenue of $3.38 million. 
Via Benzinga
3 Unstoppable Stocks to Buy Right Now
Don't let the temporary headwinds for two of these stocks fool you. 
Via The Motley Fool
ImmunoGen Boosts Annual Guidance On Upbeat Uptake Of Newly Approved Ovarian Cancer Drug
ImmunoGen Inc (NASDAQ: IMGN) shares are surging Friday morning following its impressive first-quarter performance. 
Via Benzinga
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Cash-Rich Biotech Stocks to Bet on for the Long Haul
Cash rich biotech stocks can survive while most of their peers struggle with rising interest rates. Here are three to watch. 
Via InvestorPlace
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Healthcare Stocks That Could Help Make You a Fortune
These companies are top players in their fields. 
Via The Motley Fool
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023
Via Benzinga
The Best Stocks to Invest $20,000 in Right Now
You'll want to hold on to these top stocks for the long term. 
Via The Motley Fool
Berkshire Hathaway, Gilead Sciences, Vertex Pharmaceuticals And A Break-Out Casino Stock Feature On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Gilead Sciences, Inc. 
Via Benzinga
Better Big Biotech Buy: Biogen vs. Vertex
One is slightly cheaper than the other. 
Via The Motley Fool
Have $1,000? 2 Explosive Growth Stocks to Buy and Hold No Matter What the Market Does Next
A volatile market can be an investor's friend. 
Via The Motley Fool
Got $5,000? Buy and Hold These Fast-Growing Stocks for Years
These companies have doubled their sales within the past five years. 
Via The Motley Fool
3 High-Growth Biotech Stocks Poised for Success in 2023
If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity 
Via InvestorPlace
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.